Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 5, 2007, Pages 627-636

  Chow, Tiffany W ^a,b,c   Pollock, Bruce G ^c   Milgram, Norton W ^c,d  

^a BAYCREST CENTRE FOR GERIATRIC CARE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d CanCog Technologies Incorporated   (Canada)

Author keywords

Alzheimer's disease; Amyloid precursor protein; APP ectodomain; Carbonic anhydrase; Selective serotonergic reuptake inhibitor

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CARBONATE DEHYDRATASE; CHOLINESTERASE INHIBITOR; CITALOPRAM; DIMERCAPROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DONEPEZIL; FENFLURAMINE; FLUOXETINE; PAROXETINE; PERPHENAZINE; PLACEBO; PROTEIN S100B; RIVASTIGMINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TACRINE; TACRINE DERIVATIVE; ZIMELDINE;

ALZHEIMER DISEASE; BEHAVIOR CONTROL; BEHAVIOR DISORDER; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COCHRANE LIBRARY; COGNITION; CONCENTRATION LOSS; DEMENTIA; DEPRESSION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; DRUG WITHDRAWAL; ENZYME ACTIVATION; EVIDENCE BASED MEDICINE; HIPPOCAMPUS; HUMAN; IRON CHELATION; MEDLINE; MEMORY DISORDER; MESH HEADING; MOOD DISORDER; NERVE CELL GROWTH; NONHUMAN; PROTEIN DOMAIN; REVIEW; SYSTEMATIC REVIEW; TRAUMATIC BRAIN INJURY;

EID: 36048937958     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Arjona AA, Pooler AM, Lee RK, Wurtman RJ. 2002. Effect of a 5-HT(2C) serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs. Brain Research, 951:135-40
2. Bains J, Birks JS, Dening TR. 2005. Antidepressants for treating depression in dementia. Cochrane Database of Systematic Reviews.
3. Blennow K, Wallin A, Gottfries CG, Lekiman A, Karlsson 1, Skoog I, Svennerhohn L. 1992. Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease. Neurobiology of Aging, 13:107-113.
4. Bowen DM, Palmer AM, Francis PT, Procter AW, Lowe SL. 1988. "Classical" neurotransmitters in Alzheimer disease In Aging and the Brain (Ed, Terry R. D.) Raven Press, New York, pp. 115.
5. Braak H, Braak E. 199 1. Neuropathological staging of Alzheiiner-related changes. Acta Neurepathologica, 82:239-59.
6. Brane G, Gottfries CG, Blennow K, Karlsson 1, Lekman A, Parnetti L, Svennerholm L, Wallin A. 1989. Monoamine metabolites in cerebrospinal fluid and behavioral ratings in patients with early and late onset of Alzheimer dementia. Alzheimer Dis Assoc Disord., 3:148-56.
7. Bremner JD, Vermetten E. 2004. Neuroanatornical changes associated with pharmacotherapy in posttraumatic stress disorder. Annals of the New York Academy of Sciences, 1032:154-7.
8. Burt DB, Zembar MJ, Niederehe G. 1995. Depression and memory impairment: a meta-analysis of the association, its pattern, and specificity. Psychological Bulletin, 117:285-305.
9. Calabrese F, Molteni R, Maj PF, Cattaneo A, Germarelli M, Racagni G, Riva MA. 2007. Chronic Duloxetine Treatment Induces Specific Changes in the Expression of BDNF Transcripts and in the Subcellular Localization of the Neurotrophin Protein. Neuropsychophannacology, [Epub ahead of print].
10. Carlini VP, Gaydou RC, Schioth HB, de Barioglio SR. 2007. Selective serotonin reuptake inhibitor (fluoxetine) decreases the effects of ghrelin on memory retention and food intake. Regulatory Peptides, 140:65-73.
11. Casini A, Caccia S, Scozzafava A, Supuran CT. 2003. Carbonic anhydrase activators. The selective serotonin reuptake inhibitors fluoxetine, sertralitie and citalopram are strong activators of isozymes I and II. Bioorganic & Medicinal Chemistry Letters, 13:2765-8
12. Chen CP, Eastwood SL, Hope T, McDonald B, Francis PT, Esiri MM. 2000. Immunocytochemical study of the dorsal and median raphe nuclei in patients with Alzheimer's disease prospectively assessed for behavioural changes. Neuropathology and Applied Neurobiology, 26:571-2.
13. Chen CPLH, Adler JT, Bowen DM. 1996. Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and medication. Journal of Neurochemistry, 66:1592-8.
14. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P, AD2000 Collaborative Group 2004. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet, 363:2105-15.
15. Cutler NR, Haxby J, Kay AD, Narang PK, Lesko LJ, Costa JL, Ninos M, Linnoila M, Potter WZ, Renfrew J, et al. 1985. Evaluation of zimeldine in Alzheimer's disease. Cognitive and biochemical measures. Arch Neurol, 42:744-8.
16. Delis DC, Kramer JH, Kaplan E, Ober BA. 1987. Harcourt Brace Jovanovicb, Inc., San Antonio.
17. Dong H, Goico B, Martin M, Csernansky CA, Bertchume A, Csernansky JG. 2004. Modulation of hippocampal cell proliferation, memory, and amyloid plaque deposition in APPsw (Tg2576) mutant mice by isolation stress. Neuroscience, 127:601-9.
18. Dumont GJ, de Visser SJ, Cohen AF, van Gerven JM, Biomarker Working Group of the German Association for Applied Human Pharmacology 2005. Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects. British Journal of Clinical Pharmacology, 59:495-510.
19. Eckert A, Cotman CW, Zerfass R, Hennerici M, Muller WE. 1998. Lymphocytes as cell model to study apoptosis in Alzheimer's disease: vulnerability to programmed cell death appears to be altered. Journal of Neural Transmission Supplement, 54:259-67.
20. Egashira N, Matsumoto Y, Mishima K, Iwasaki K, Fujioka M, Matsushita M, Shoyama Y, Nishimura R, Fujiwara M. 2006. Low dose citalopram reverses memory impairment and electroconvulsive shock-induced immobilization. Pharmacology, Biochemistry and Behavior, 83:161-7.
21. Etcheberrigaray R, Bhagavan S. 1999. Ionic and signal transduction alterations in Alzheimer's disease: relevance of studies on peripheral cells. Molecular Neurobiology, 20:93-109.
22. Finkel SI, Mintzer JE, Dysken M, Krishnan KR, Burt T, McRae T. 2004. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. International journal of geriatric psychiatry, 19:9-18.
23. Gobbi G, Blier P. 2005. Effect of neurokinin-1 receptor antagonists on serotoninergic, noradrenergic and hippocampal neurons: comparison with antidepressant drugs. Peptides, 26:1383-93.
24. Griffin WS, Sheng JG, Mrak RE. 1998. Senescence-accelerated overexpression of S100beta in brain of SAMP6 mice. Neurobiology of Aging, 19:71-6.
25. Hajos-Korcsok E, McTavish SF, Sharp T. 2000. Effect of a selective 5-hydroxytryptamine reuptake inhibitor on brain extracellular noradrenaline: microdialysis studies using paroxetine. European Journal of Pharmacology, 407:101-7.
26. Haring JH, Hagan A, Olson J, Rodgers B. 1993. Hippocampal serotonin levels influence the expression of S 100 beta detected by inummocytochemistry. Brain Research, 631:119-23.
27. Huang SC, Tsai SJ, Chang JC. 2004. Fluoxetine-induced memory impairment in four family members. International Journal ofPsychiatry in Medicine, 34:197-200.
28. Jack, CRJ, Shiung MM, Weigand SD, O'Brien PC, Gunter JL, Boeve BF, Knopman DS, Smith GE, Ivnik RJ, Tangalos EG, Petersen RC. 2005. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology, 65:1227-31.
29. Joss JD, Burton RM, Keller CA. 2003. Memory loss in a patient treated with fluoxetine. The Annals of Pharmacotherapy, 37:1800-3.
30. Jossan SS, Adem A, Winblad B, Oreland L. 1992. Characterisation of dopamine and serotonin uptake inhibitory effects of tetrahydroaminoacridine in rat brain. Pharmacol Toxicol, 71:213-5.
31. Khaliq S, Haider S, Ahmed SP, Perveen T, Haleem DJ. 2006. Relationship of brain tryptophan and serotonin in improving cognitive performance in rats. Pakistan Journal of Pharmaceutical Sciences, 19:11-5.
32. Kogen H, Toda N, Tago K, Marumoto S, Takami K, Ori M, Yamada N, Koyama K, Naruto S, Abe K, Yamazaki R, Hara. T, Aoyagi A, Abe Y, Kaneko T. 2002. Design and synthesis of dual inhibitors of acetyl-cholinesterase and serotonin transporter targeting potential agents for Alzheimer's disease. Organic Letters, 4:3359-62
33. Lanctot KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, Einarson TR. 2003. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. Canadian Medical Association Journal, 169:557-64.
34. Lotrich FE, Pollock BG. 2005. Candidate genes for antidepressant response to selective serotonin reuptate inhibitors. Neuropsychiatr Dis Treat, 1:17-35.
35. Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele CD, Munro C, Baker AS, Sheppard JM, Frangakis C, Brandt J, Ribins PV. 2003. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry, 60:737-46.
36. MacPherson A, Dinkel K, Sapolsky R. 2005. Glucocorticoids worsen excitotoxin-induced expression of pro-inflammatory cytokines in hippocampal cultures. Experimental Neurology, 194:376-83.
37. Mattson MP, Maudsley S, Martin B. 2004. BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegerative disorders. Trends in Neuroscience, 27:589-94.
38. Meeter M, Talamini L, Schmitt JA, Riedel WJ. 2006. Effects of 5-HT on memory and the hippocampus: model and data. Neuropsychopharmacology, 31:712-20.
39. Meneses A. 1998. Physiological, pathophysiological and therapeutic roles of 5-HT systems in learning and memory. Reviews in the Neurosciences, 9:275-89.
40. Meneses A. 2001. Effects of the 5-HT(6) receptor antagonist Ro 04-6790 on learning consolidation. Behav Brain Res, 118:107-10.
41. Meneses A. 2003. A pharmacological analysis of an associative learning task: 5-HT1 to 5-HT7 receptor subtypes functionon Pavlovian/instrumental autoshaped memory. Learning and Memory, 10:363-72.
42. Meneses A, Hong E. 1995. Effect of fluoxetine on learning and memory involves multiple 5-HT systems. Pharmacol Biochem Behav, 52:341-6.
43. Meneses A, Terron JA. 2001. Role of 5-HT(1 A) and 5-HT(7) receptors in the facilitatory response induced by 8-OH-DPAT on learning consolidation. Behav Brain Res, 121:21-8.
44. Meneses A, Terron JA, Hong E. 1997. Effects of the 5-HT receptor antagonists GR127935 (5-HT1B/1D) and NOL100907 (5-HT2A) in the consolidation of learning. Behav Brain Res, 89:217-23.
45. Mitchell ES, Neumaier JF. 2005. 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacology and Therapeutics, 108:320-33.
46. Mme-Filali O, El Mansari M, Espana A, Sanchez C, Haddjeri N. 2006. Allosteric modulation of the effects of the 5-HT reuptake inhibitor escitalopram on the rat hippocampal synaptic plasticity. Neuroscience Letters, 395:23-7.
47. Morse LJ, Payton SM, Cuny GD, Rogers JT. 2004. FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein. Journal of Molecular Neuroscience, 24:129-36
48. National Institute on Aging, a. R. I. W, G. o. D. C. f. t. N. A. o. A. s. D. 1997. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiology of Aging, 18:S1-S2.
49. Nazarali AJ, Reynolds GP. 1992. Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: a post-mortem study. Cellular and Molecular Neurobiology, 12:591-7.
50. Nibuya M, Nestler EJ, Duman RS. 1996. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. Journal of Neuroscience, 16:2365-72.
51. Nyth AL, Gottfries CG. 1990. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry, 157:894-901.
52. Ohashi S, Matsumoto M, Otani H, Mori K, Togashi H, Ueno K, Kaku A, Yoshioka M. 2002. Changes in synaptic plasticity in the rat hippocampomedial prefrontal cortex pathway induced by repeated treatments with fluvoxamine. Brain Research, 949:131-8.
53. Page ME, Abercrombie ED. 1997. An analysis of the effects of acute and chronic fluoxetine on extracellular norepinephrine in the rat hippocampus during stress. Neuropsychopharmacology, 16:419-25.
54. Palotas A, Kalman J, Palotas M, Juhasz A, Janka Z, Penke B. 2002. Beta-amyloid induced increase in the resting intracellular calcium concentration gives support to tell Alzheimer lymphocytes from control ones. Brain Research Bulletin, 58:203-5.
55. Palotas A, Puskas LG, Kitajka K, Palotas M, Molnar J, Pakaski M, Janka Z, Penke B, Kalman J. 2004. The effect of citalopram. on gene expression profile of Alzheimer lymphocytes. Neurochemical Research, 29:1563-70.
56. Payton S, Cahill CM, Randall JD, Gullans SR, Rogers JT. 2003. Drug discovery targeted to the Alzheimer's APP mRNA 5′-untranslated region: the action of paroxetine and dimercaptopropanol. Journal of Molecular Neuroscience, 20:267-75.
57. Pollock BG, Mulsant BH, Rosen J, Sweet R, Mazumdar S, Bharucha A, Marin R, Jacob NJ, Huber KA, Kastango KB, Chew ML. 2002. Comparison of Citalopram, Perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. American Journal of Psychiatry, 159:460-65.
58. Pollock BG, Rosen J, Mulsant BH. 1999. Antipsychotics and selective serotonin reuptake inhibitors for the treatment of behavioral disturbances in dementia of the Alzheimer type: a review of clinical data. Consultant Pharmacist, 11:1251-58.
59. Procter AW, Francis PT, Stratmann GC, Bowen DM. 1992. Serotonergic pathology is not widespread in Alzheimer's patients without prominent aggressive symptoms. Neurochemical Research, 17:917-22.
60. Reeves R, Yao J MR C, Buck S, Zhang X, Yarowsky P, Gearhart JD, Hilt DC. 1994. Astrocytosis and axonal proliferation in the hippocampus of S100b transgenic mice. Proceedings of the National Academy of Science USA, 91:5359-63.
61. Reinikainen KJ, Soininen H, Riekkinen PJ. 1988. A post-mortern study of noradrenergic, serotonergic and gabaergic neurons in Alzheimer's disease. Journal of the Neurological Sciences, 84:101-16.
62. Sapolsky R. 2003. Taming stress. Scientific American, 289:86-95.
63. Schechter LE, Smith DL, Rosenzweig-Lipson S, Sukoff SJ, Dawson LA, Marquis K, Jones D, Piesla M, Andree T, Nawoschik S, Harder JA, Womack MD, Buccafirsco J, Terry AV, Hoebel B, Rada P, Kelly M, Abou-Gharbia M, Barrett JE, Childers WJ. 2005. Lecozotan (SRA-333): a selective serotonin 1 A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties. Pharmacol Exp Ther, 3 14:1274-89.
64. Schiapparelli L, Del Rio J, Frechilla D. 2005. Serotonin 5-HT receptor blockade enhances Ca(2+)/calmodulin-dependent protein kinase II function and membrane expression of AMPA receptor subunits in the rat hippocampus: implications for memory formation. Journal of Nerochemistry, 94:884-95.
65. Sheline YI, Sanghavi M, Mintun MA, Gado ME. 1999. Depression duration but not age predicts hippocampal volume loss m medically healthy women with recurrent major depression. Journal of Neuroscience, 19:5034-43.
66. Sheng JG, Mrak RE, Rovnaghi CR, Kozlowska E, Van Eldik LJ, Griffin WS. 1996. Human brain S 100 beta and S 100 beta mRNA expression increases with age: pathogenic implications for Alzheimer's disease. Neurobiology of Aging, 17:359-63.
67. Sjogren M, Minthon L, Passant U, Blennow K, Wallin A. 1998. Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease. Neurobiology of Aging, 19:379-84.
68. Smith JE, Lakoski JM. 1998. Cellular electrophysiological effects of chronic fluoxetine and duloxetine administration on serotonergic responses in the aging hippocampus. Synapse, 30:318-28.
69. Stewart CA, Reid IC. 2000. Repeated ECS and fluoxetine administration have equivalent effects on hippocampal synaptic plasticity. Psychopharmacology, 148:217-23.
70. Sun M.-K, Alkon DL. 2001. Pharmacological enhancement of synaptic efficacy, spatial learning, and memory through carbonic anhydrase activation in rats. The Journal of Pharmacology and Experimental Therapeutics, 297:961-67.
71. Thomas DN, Nutt DJ, Holman RB. 1998. Sertraline, a selective serotonin reuptake inhibitor modulates extracellular noradrenaline in the rat frontal cortex. Journal of Psychopharmacology, 12:366-70.
72. Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A. 2006. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. Journal of Psychopharmacology, 20:211-25.
73. Tohgi H, Abe T, Takahashi S, Saheki M, Kimura M. 1995. Indoleamine concentrations in cerebrospinal fluid from patients with Alzheimer type and Binswanger type dementias before and after administration of citalopram, a synthetic serotonin uptake inhibitor. Journal of Neural Transmission. Parkinsons Disease and Dementia Section, 9:121-31.
74. Ueda S, Sakakibara S, Yoshirnoto K. 2005. Effect of long-lasting serotonin depletion on environmental enrichment-induced neurogenesis in adult rat hippocampus and spatial learning. Neuroscience, 135:395-402.
75. van der Veen FM, Evers EA, van Deursen JA, Deutz NE, Backes WH, Schmitt JA. 2006. Acute tryptophan depletion reduces activation in the right hippocampus during encoding in an episodic memory task. Neuroimage, 31:1188-96.
76. Vizi ES, Zsilla G, Caron MG, Kiss JP. 2004. Uptake and release of norepinephrine by serotonergic terminals in norepinephrine transporter knock-out mice: implications for the action of selective serotonin reuptake inhibitors. Journal of Neuroscience, 24:7888-94.
77. Wechsler D. 1987. Harcourt, Brace, Jovanovich, Inc, San Antonio.